Literature DB >> 17571265

Neurological manifestations of connective tissue diseases mimicking multiple sclerosis.

Sigliti-Henrietta Pelidou1, Sotiris Giannopoulos, Sotiria Tzavidi, Niki Tsifetaki, Georgios Kitsos, Dimitrios Stefanou, Vassiliki Kostadima, Alexandros A Drosos, Athanassios P Kyritsis.   

Abstract

The objective of the study was to analyze retrospectively the clinical, laboratory and imaging findings of multiple sclerosis (MS), such as the manifestations in a cohort of 132 patients referred to the neurology in and outpatient clinic. The proposed clinical and laboratory diagnostic criteria for MS and connective tissue disorders were systematically assessed in 132 consecutive patients. Cerebrospinal fluid serology and brain or spinal cord MRI were studied in all cases. In patients suspected for connective tissue disorder, schirmer test, rose bengal staining and biopsy of minor salivary glands were performed. A total of 115 (87%) patients were diagnosed to have definite MS, while 17 (13%) were diagnosed to have connective tissue disorder. Positive neurological and MRI findings were observed in both groups. The majority of patients with connective tissue disorder demonstrated extra-neurological manifestations like Raynaud's phenomenon, arthritis, livedo reticularis, purpura and presence of multiple autoantibodies in their sera. All patients with MS should be screened systematically for connective tissue disorder. In the absence of pathognomonic clinical and laboratory findings, the diagnosis of MS is a diagnosis of exclusion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17571265     DOI: 10.1007/s00296-007-0384-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  20 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Cervical cord magnetic resonance imaging findings in systemic immune-mediated diseases.

Authors:  M Rovaris; B Viti; G Ciboddo; R Capra; M Filippi
Journal:  J Neurol Sci       Date:  2000-06-15       Impact factor: 3.181

3.  Central nervous system involvement in Sjogren's syndrome.

Authors:  F C Soliotis; C P Mavragani; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

4.  Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.

Authors:  Lindsey A Criswell; Kirsten A Pfeiffer; Raymond F Lum; Bonnie Gonzales; Jill Novitzke; Marlena Kern; Kathy L Moser; Ann B Begovich; Victoria E H Carlton; Wentian Li; Annette T Lee; Ward Ortmann; Timothy W Behrens; Peter K Gregersen
Journal:  Am J Hum Genet       Date:  2005-02-17       Impact factor: 11.025

Review 5.  Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.

Authors:  M J Cuadrado; M A Khamashta; A Ballesteros; T Godfrey; M J Simon; G R Hughes
Journal:  Medicine (Baltimore)       Date:  2000-01       Impact factor: 1.889

6.  Prevalence of primary Sjögren's syndrome in patients with multiple sclerosis.

Authors:  J Miró; J L Peña-Sagredo; J Berciano; S Insúa; C Leno; R Velarde
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

Review 7.  Demyelination in rheumatic diseases.

Authors:  A Theodoridou; L Settas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

8.  Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients.

Authors:  Sophie Delalande; Jérôme de Seze; Anne-Laure Fauchais; Eric Hachulla; Tanya Stojkovic; Didier Ferriby; Sylvain Dubucquoi; Jean-Pierre Pruvo; Patrick Vermersch; Pierre-Yves Hatron
Journal:  Medicine (Baltimore)       Date:  2004-09       Impact factor: 1.889

9.  Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus.

Authors:  M Mandel; M Gurevich; R Pauzner; N Kaminski; A Achiron
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  4 in total

Review 1.  Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention.

Authors:  Andrew J Solomon; Brian G Weinshenker
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

2.  Clustering of organ-specific autoimmunity: a case presentation of multiple sclerosis and connective tissue disorders.

Authors:  Nilufer Kale; Murat Icen; Jale Agaoglu; Isil Yazici; Osman Tanik
Journal:  Neurol Sci       Date:  2008-10-14       Impact factor: 3.307

3.  Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity.

Authors:  Dimitris K Karathanasis; Anna Rapti; Adrianos Nezos; Charalampos Skarlis; Constantinos Kilidireas; Clio P Mavragani; Maria Eleftheria Evangelopoulos
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

4.  A challenging entity: multiple sclerosis or collagen tissue disorders: A case series of 6 patients.

Authors:  Raida Ben Salah; Yosra Cherif; Faten Frikha; Dammak Chifaa; Mouna Snoussi; Moez Jallouli; Sameh Marzouk; Mhiri Chokri; Zouhir Bahloul
Journal:  Caspian J Intern Med       Date:  2017
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.